IQVIA (NYSE:IQV) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a report published on Friday.

IQV has been the topic of several other reports. Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Price Performance

Shares of IQVIA stock traded up $1.55 on Friday, hitting $219.23. The company had a trading volume of 1,418,430 shares, compared to its average volume of 1,101,442. IQVIA has a 52 week low of $190.20 and a 52 week high of $261.73. The company has a market cap of $39.79 billion, a PE ratio of 28.76, a PEG ratio of 2.26 and a beta of 1.51. The business has a 50-day simple moving average of $231.00 and a 200-day simple moving average of $229.31. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA during the 3rd quarter valued at about $147,683,000. 1832 Asset Management L.P. raised its position in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in IQVIA in the second quarter valued at approximately $70,610,000. Impax Asset Management Group plc grew its position in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.